Heparin-binding protein levels predict unfavorable outcome in COVID-19 pneumonia: A post-hoc analysis of the SAVE trial

Di |2024-03-22T16:00:00+01:00Marzo 22nd, 2024|Categorie: Coronavirus PubMed|

We aimed to evaluate heparin-binding protein (HBP) as a marker of prognosis of unfavorable outcome in COVID-19 pneumonia. This was a post-hoc analysis of the SAVE clinical trial investigating anakinra treatment, guided by suPAR (soluble urokinase plasminogen activator receptor) levels ≥6 ng/ml, for the prevention of severe respiratory failure (SRF) in hospitalized patients with COVID-19 pneumonia. Baseline HBP plasma levels were measured in 534 patients by fluorescence dry quantitative...

Moral Stress and Moral Distress: Confronting Challenges in Healthcare Systems under Pressure

Di |2023-06-22T03:00:00+02:00Giugno 22nd, 2023|Categorie: Coronavirus PubMed|

Stresses on healthcare systems and moral distress among clinicians are urgent, intertwined bioethical problems in contemporary healthcare. Yet conceptualizations of moral distress in bioethical inquiry often overlook a range of routine threats to professional integrity in healthcare work. Using examples from our research on frontline physicians working during the COVID-19 pandemic, this article clarifies conceptual distinctions between moral distress, moral injury, and moral stress and...

Cutaneous Adverse Events Following 771 Doses of the Inactivated and mRNA Covid-19 Vaccines: a Survey Study Among Health Care Providers

Di |2022-07-01T06:00:00+02:00Luglio 1st, 2022|Categorie: Coronavirus PubMed|

INTRODUCTION: As Coronavirus disease 19 (Covid-19) still continues to affect humanity worldwide, different types of Covid-19 vaccines are being administered to maintain immunization against Covid-19. As both the inactivated and mRNA vaccines are now being applied prevalently, systemic adverse events along with cutaneous side effects are frequently being reported in the literature.

Coronaviruses in wild animals sampled in and around Wuhan at the beginning of COVID-19 emergence

Di |2022-06-30T13:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

Over the last several decades, no emerging virus has had a profound impact on the world as the SARS-CoV-2 that emerged at the end of 2019 has done. To know where severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated from and how it jumped into human population, we immediately started a surveillance investigation in wild mammals in and around Wuhan when we determined the agent. Herein, coronaviruses were screened in the lung, liver, and intestinal tissue samples from fifteen...

Vasoactive intestinal peptide: a potential target for antiviral therapy

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

Viral infection is clinically common and some viral diseases, such as the ongoing global outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), have high morbidity and mortality. However, most viral infections are currently lacking in specific therapeutic agents and effective prophylactic vaccines, due to inadequate response, increased rate of drug resistance and severe adverse side effects. Therefore, it is urgent to find new...

Spatially Patterned Neutralizing Icosahedral DNA Nanocage for Efficient SARS-CoV-2 Blocking

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

Broad-spectrum anti-SARS-CoV-2 strategies that can inhibit the infection of wild-type and mutant strains would alleviate their threats to global public health. Here, we propose an icosahedral DNA framework for the assembly of up to 30 spatially arranged neutralizing aptamers (IDNA-30) to inhibit viral infection. Each triangular plane of IDNA-30 is composed of three precisely positioned aptamers topologically matching the SARS-CoV-2 spike trimer, thus forming a multivalent spatially patterned...

Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

We hereby introduce a sensitive fast straightforward spectrofluorometric method for the estimation of remdesivir and favipiravir. The two drugs are prescribed in some regimens to treat COVID-19 pandemic disease, which is caused by SARS-CoV-2. The method is based on the first derivative synchronous spectrofluorimetry approach for the measurement of remdesivir and favipiravir. This was accomplished at 251 nm and 335 nm respectively using the first derivative order at delta lambda of 140 nm. A...

Antibody response to BNT162b2 mRNA vaccine in gingival crevicular fluid

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

CONCLUSION: This study establishes GCF and saliva as viable alternative non-invasive sources to monitor levels of antibodies following vaccination, with GCF demonstrating feasibility as a biofluid source for the detection of antibodies against SARS-CoV-2 S1-RBD antigen. This article is protected by copyright. All rights reserved.

Interleukin-6 blocking therapy for COVID-19: From immune pathogenesis to clinical outcomes

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

As a newly emerged infectious disease, the coronavirus disease 2019 (COVID-19) has caused millions of deaths, resulting in a global health challenge. Currently, several vaccines have been approved with significant benefits against disease transmission. However, effective therapies are still needed for the clinical management of infected COVID-19 patients. Available evidence has indicated elevated levels of proinflammatory cytokines, including interleukin-6 (IL-6), in COVID-19 patients, with...

Torna in cima